SELINEXOR PLUS RUXOLITINIB IN JAK INHIBITOR–NAÏVE MYELOFIBROSIS: PHASE 3 SENTRY TRIAL (SIE 2026) - Oct 6, 2026 - Abstract #C031; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 3; "S+R significantly improved spleen response vs R alone with earlier, deeper, and sustained response rates, comparable symptom improvement from baseline, and a manageable safety profile. Improved spleen response, promising OS signal, and VAF reductions observed in SEN- TRY position S+R as a novel combination for frontline MF treatment."
IO biomarker • P3 data • Myelofibrosis • Myeloproliferative Neoplasm
|
|
A. Patriarca1; P. Bose2; H. Ali3; H. Al-Ali4; J. V. Garcia Gutierrez5; S. Grosicki6; Z. Grudeva-Popova7; C. Harrison8; J. Hong9; H. Hou10; T. Jain11; M. Kwiatek12; M. Loschi13; F. Passamonti14; N. Podoltsev15; R. Rampal16; S. Tantravahi17; L. G. Urian18; D. Miljkovic19; Y. Chai20; P. Taverna20; T. Mark20; A. Sadiq20; R. Rangwala20; P. Vachhani21; J. Mascarenhas22
|